Kaicheng Zhou

Shanghai, 201203, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Integrative Transcriptomic Analysis Identifies COL3A1 as a Potential Tumor-Intrinsic Therapeutic Target in NSCLC.

Integrative Transcriptomic Analysis Identifies COL3A1 as a Potential Tumor-Intrinsic Therapeutic Target in NSCLC.

Journal: Biomedicines

Published: March 19, 2026

Oncogenic KRAS represses the dependence receptor UNC5C via ERK2-FOS signaling in non-small cell lung cancer.

Oncogenic KRAS represses the dependence receptor UNC5C via ERK2-FOS signaling in non-small cell lung cancer.

Journal: The Journal of biological chemistry

Published: November 07, 2025

Anti-ANGPTL3 antibody and IL-22 fusion protein mitigate nephrotic syndrome via mitochondrial protection, anti-apoptosis, and autophagy suppression.

Anti-ANGPTL3 antibody and IL-22 fusion protein mitigate nephrotic syndrome via mitochondrial protection, anti-apoptosis, and autophagy suppression.

Journal: Antibody therapeutics

Published: September 05, 2025

Precision-engineered STING agonist nanoparticles enable coordinated mucosal-systemic immunity for durable pan-β-coronavirus protection.

Precision-engineered STING agonist nanoparticles enable coordinated mucosal-systemic immunity for durable pan-β-coronavirus protection.

Journal: Nature nanotechnology

Published: August 05, 2025

ANGPTL3 nanobody-FGF21 fusion protein ameliorates metabolic dysfunction-associated fatty liver disease via regulation of lipid and glucose metabolism and attenuation of oxidative stress.

ANGPTL3 nanobody-FGF21 fusion protein ameliorates metabolic dysfunction-associated fatty liver disease via regulation of lipid and glucose metabolism and attenuation of oxidative stress.

Journal: International journal of biological macromolecules

Published: June 18, 2025

Scarless circular mRNA-based CAR-T cell therapy elicits superior antitumor efficacy.

Scarless circular mRNA-based CAR-T cell therapy elicits superior antitumor efficacy.

Journal: Signal transduction and targeted therapy

Published: June 05, 2025

TargetPair: A Single Cell-omics Resource of Clinical Trials-derived Therapeutical Target Combinations for Cancer Therapy.

TargetPair: A Single Cell-omics Resource of Clinical Trials-derived Therapeutical Target Combinations for Cancer Therapy.

Journal: Journal of molecular biology

Published: May 13, 2025

NamiRNA-Enhancer Network: The Changing Era Challenge and Chance of miRNA.

NamiRNA-Enhancer Network: The Changing Era Challenge and Chance of miRNA.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: April 15, 2025

HBV sequence integrated to enhancer acting as oncogenic driver epigenetically promotes hepatocellular carcinoma development.

HBV sequence integrated to enhancer acting as oncogenic driver epigenetically promotes hepatocellular carcinoma development.

Journal: Journal of experimental & clinical cancer research : CR

Published: March 08, 2025

Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy.

Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy.

Journal: Journal for immunotherapy of cancer

Published: August 14, 2024

Modulating autophagy to boost the antitumor efficacy of TROP2-directed antibody-drug conjugate in pancreatic cancer.

Modulating autophagy to boost the antitumor efficacy of TROP2-directed antibody-drug conjugate in pancreatic cancer.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: July 31, 2024

Highly homologous miR-135a and miR-135b converting non-small cell lung cancer from suppression to progression via enhancer switching.

Highly homologous miR-135a and miR-135b converting non-small cell lung cancer from suppression to progression via enhancer switching.

Journal: Human molecular genetics

Published: December 11, 2023

Showing 1-12 of 15

Last Updated: 09/26/2026